Some Black women with hormone receptor (HR)-positive/HER2-negative breast cancer had worse outcomes compared with White women despite having similar genetic recurrence risk scores, according to data from the 2022 San Antonio Breast Cancer Symposium. Yara Abdou, MD, assistant professor at the University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center, presented results of an analysis of clinical outcomes respective to race and ethnicity in women enrolled in the RxPONDER trial. The trial aimed to assess the value of the 21-gene recurrence score (RS) in patients with ...
SABCS 2022
The San Antonio Breast Cancer Symposium (SABCS) is the largest and most prestigious scientific gathering on breast cancer research. Topics cover new treatments, patient care, surgical and reconstructive techniques, health equity, telemedicine, and more. Find highlights from the sessions that are most relevant to oncology nurses.
Advertisement
Results from the DESTINY-Breast03 study indicate survival advantage with the antibody drug conjugate.
The local recurrence rates were optimistic for women with multiple ipsilateral breast cancer in one clinical trial.
Advertisement
Learn what oncology nurses should know about sarcopenia and why it's an increasingly recognized predictor of poor prognosis.
Proactive symptom management and patient education are essential, as treatment completion remains a challenge.
New research suggests that screening guidelines should be refined to account for asymptomatic brain metastases.
Learn what new research shows about the key elements that establish trust between patients and health care professionals.
Expressive writing may be a feasible and acceptable psychosocial treatment for rural survivors of breast cancer.
The study also showed that depression is negatively associated with medication adherence.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.